Lucentis Prefilled Syringe

Lucentis (ranibizumab) is an injectable medication used to treat neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. It helps prevent vision loss by inhibiting abnormal blood vessel growth and fluid leakage in the retina.

Lucentis is administered via intravitreal injection directly into the eye by a qualified ophthalmologist, typically once a month or as advised. The procedure is done in a sterile clinical setting to minimize the risk of infection.

Mild eye discomfort, redness, or floaters are common after the injection. Vision may be temporarily blurred, but serious complications like eye infection or retinal detachment are rare and require immediate medical attention.

Lucentis targets vascular endothelial growth factor A (VEGF-A), which plays a key role in the formation of abnormal blood vessels in the eye. By blocking VEGF-A, it helps preserve vision and reduce retinal swelling.

Lucentis does not cure retinal diseases but helps manage them over time. Regular follow-up and repeat injections are typically necessary to maintain visual benefits and monitor for disease progression.